Sera (n ‫؍‬ 188) from 29 patients with first-episode genital herpes simplex virus type 2 (HSV-2) infections were tested by POCkit-HSV-2 and Western blot (WB) to determine the speed of seroconversion. The median time to detection of HSV-2 antibody was 13 days (range, 3 to 102 days) by the POCkit-HSV-2 test versus 13 days (range, 2 to 58 days) for WB.
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The seroprevalence of herpes simplex virus type 2 (HSV-2) has increased by more than 30% over the past 2 decades (8) . Most HSV-2-seropositive individuals (75 to 90%) are unaware that they are infected (8, 20) . Type-specific antibody detection methods can identify genital HSV-2 infections in individuals with mild or unrecognized clinical manifestations (12, 13) . A number of tests based on the type-specific glycoprotein G (gG) are in use in the United Kingdom, Australia, and Europe (7, 10, 18, 19) . Such tests are much more accurate than currently available tests based on crude antigen mixtures (1) but are not widely available in the United States (3, 14) . One product, the POCkit-HSV-2 test, provides a rapid (6-min) point-of-care format for detecting antibody to gG-2 in capillary blood. Serum antibodies also can be detected by the POCkit-HSV-2 test with sensitivities of 96% compared with Western blot (WB) and 92% compared with a gG-2 type-specific enzyme-linked immunosorbent assay (ELISA) (Gull Laboratories, Salt Lake City, Utah). Specificities were 97 and 100% compared with WB and ELISA, respectively (5) .
A rigorous and practical measure of sensitivity is the time after infection required for a test to detect seroconversion. We used the POCkit-HSV-2 test and WB to test 188 sera (3 to 11 sera per patient; median, 7 sera) from 29 patients with culturedocumented genital HSV-2 infections: 17 patients were HSV seronegative (primary episodes) and 12 were HSV-1 seropositive (nonprimary episodes) at the time they presented with genital herpes. The median time from the onset of symptoms to the first clinic visit was 4.5 days (range, 1 to 7 days). The date of a patient's first clinic visit was recorded as day 0.
The POCkit-HSV-2 test was performed by allowing the diluted sample, and then the developing reagent, to pass through a membrane containing a dot with affinity-purified gG-2 and a second dot with human immunoglobulin G (IgG). If both dots turned red, the test was scored positive; if only the human IgG dot changed color, the test was negative. If neither dot changed color, the test was invalid. No invalid test results occurred. Thirty sera (16%) did not pass through the membrane on the first attempt; therefore, fresh portions were filtered and tested successfully.
WB results were tallied for two types of antibody profiles. First, early HSV-2 seroconversion gives a limited WB profile that usually lacks the gG-2 band (2, 16) . This result is confirmed by preadsorption of the serum against HSV-1 and HSV-2 antigens and repetition of the test (2) . Second, we also recorded the earliest time at which a full HSV-2 antibody profile developed. These profiles all contained the gG-2 band, and preadsorption of the serum was not necessary. This result represents the earliest time that a single serum could give an unequivocal profile for HSV-2.
The median number of days required by the POCkit-HSV-2 test to detect HSV-2 antibody in the 29 seroconverting subjects was 13 (range, 3 to 102) (Fig. 1) . Antibody responses to primary HSV-2 episodes required 19 days (range, 7 to 102 days), while for those patients with prior HSV-1 antibodies (nonprimary episodes) only 8 days was required (range, 3 to 45 days [P ϭ 0.003; Wilcoxon rank-sum test]). This difference suggests an anamnestic response to type-common epitopes in the gG-2 used in the POCkit-HSV-2 test. Recent epitope mapping studies suggest that the human antibody response is to an immunodominant region of gG that has substantial sequence homology between gG-1 and gG-2 (15). Hashido and colleagues (9) have demonstrated relatively high levels of gG-2 antibodies in nonprimary HSV-2 episodes and lower levels of gG-2 antibodies in response to primary HSV-2 episodes; such titer differences are consistent with a later time to detection of primary gG-2 antibody responses, as seen here. However, their study revealed no increase in the titer of antibody to gG-1 after infection with HSV-2. Thus, it remains unclear why gG-2 antibody responses are more pronounced in HSV-1-seropositive patients.
Limited WB profiles developed in a median of 13 days (range, 2 to 58 days) after a patient's presentation to the clinic (Fig. 1A) . Full HSV-2 profiles, including gG-2 bands, were observed at a median of 27 days (range, 11 to Ͼ114 days) after presentation (Fig. 1B) . A longer time was required for development of complete WB profiles for patients with nonprimary episodes (median, 47.5 days; range, 11 to Ͼ114 days) than for those with primary episodes (median, 23 days; range, 13 to 102 days). However, this difference did not reach statistical significance (P ϭ 0.3712; chi-square test). This finding is probably due to the difficulty of detecting HSV-2-specific bands against the background of HSV type-common antibodies in sera from patients with nonprimary episodes.
The time to seroconversion determined by the POCkit-HSV-2 test was comparable to that required to develop a limited WB antibody profile (P ϭ 0.24; Wilcoxon signed-rank test). The POCkit-HSV-2 test was markedly faster than the full WB (P Ͻ 0.001 by the paired Prentice-Wilcoxon test [17] ) (Fig.  1B) . These findings were somewhat surprising since the early WB profiles lacked gG-2 bands and since the production of antibodies to gG-2 is not felt to be among the early responses to HSV-2 infection (16). The WB method in this study uses secondary enzyme-linked reagents directed against human IgG. The POCkit-HSV-2 reagent is directed against human light-chain as well as against human heavy-chain IgG. We have shown that 47 to 52% of sera from first-episode genital HSV-2 patients have IgM to gG-2 but not IgG (6) . The POCkit-HSV-2 test may detect IgM to gG-2 in samples with undetectable levels of IgG to gG-2. This conclusion is consistent with the report by Ho et al. of early IgM responses (11) and with our previous findings from a comparison of gG-2 IgG and IgM ELISAs (Gull Laboratories) for detection of seroconversion (4). The gG-2 IgM ELISA was 9 weeks faster (median) in detecting seroconversion in patients with HSV-2 primary episodes and 16 weeks faster (median) in detecting seroconversion in patients with nonprimary episodes than the gG-2 IgG ELISA (4).
In summary, the POCkit-HSV-2 test detects seroconversion within 4 weeks of presentation of 80% of patients with HSV-2 episodes. Further study is required to confirm these findings when the test is used at the point of care with capillary blood. Also, studies to compare this test to other gG-based serology tests are needed to fully evaluate its performance. Currently WB is available to very few patients. A rapid, easily performed test such as POCkit-HSV-2 that is as sensitive as or more sensitive than WB in detecting seroconversion could greatly aid clinicians and laboratories in accurately diagnosing genital HSV-2 infections.
